Epidemiology, management, and prevention of exit site infections in peritoneal dialysis patients

Exit site infection (ESI) is a leading complication of peritoneal dialysis (PD), at an incidence of 0.6 episodes per year in the United States, and a major risk factor for catheter removal and peritonitis. An estimated 20% of all peritonitis cases are preceded by an ESI, with up to 50% of Staphylococcus aureus peritonitis associated with ESI. Gram‐negative ESIs are less associated with succeeding peritonitis than their gram‐positive counterparts, though when present, are associated with a lower peritonitis cure rate. The rate of catheter removal for refractory ESI is relatively highest in ESI due to mycobacteria (up to 40%), S. aureus (35%), Pseudomonas aeruginosa (28%), followed by Corynebacterium, Serratia, and fungi. In review of relevant literature, we found no prophylactic benefit of dressings over nondressings, specific antiseptics over normal saline, or topical honey over topical antibiotic prophylaxis, and thus recommend individualized exit site hygiene. We found topical gentamicin effective for prevention of most ESIs, including gram‐negative ESIs, and thus recommend consideration of prophylactic topical gentamicin in areas of high gram‐negative peritonitis incidence. With long‐term use, observational studies detect up to 25% of gram‐positive and 14% of gram‐negative ESIs may be mupirocin and gentamicin resistant, respectively. We review empiric and targeted ESI management, including indications for ultrasound, anti‐VMRSA, anti‐Pseudomonal, and anti‐mycobacterial antibiotic use, and catheter removal. We recommend further investigation into the earlier use of second‐line treatment agents and the utility of treating post‐infectious exit site colonization as avenues to decrease refractory and repeat ESI.